TMCnet News
Molecular Partners appoints Steven H. Holtzman as independent non-executive member to its board of directors(Tensid Regulatory Via Acquire Media NewsEdge) Molecular Partners appoints Steven H. Holtzman as independent non-executive member to its board of directors Zürich-Schlieren, September 19, 2014. Molecular Partners AG announced today the appointment of Steven H. Holtzman as an independent non-executive member of its board of directors. "We are pleased to welcome Steven to the board of Molecular Partners," said Jörn Aldag, Chairman of the Board of Directors at Molecular Partners. "He brings with him a wealth of experience in building and managing successful biotech companies at a time where Molecular Partners is significantly progressing its broad clinical and preclinical pipeline and important partnerships. He will prove invaluable to Molecular Partners in supporting many of our decisions as the company further matures." Mr. Holtzman brings considerable experience to the board of Molecular Partners. He is currently serving as Executive Vice President, Corporate Development on the Executive Committee of Biogen Idec. Prior to that, Steven Holtzman was a founder, initially Chief Executive Officer and Chairman of the Board of Infinity Pharmaceuticals, Inc., Chief Business Officer at Millennium Pharmaceuticals, Inc. and a founder and member of the Board of Directors and Executive Vice President of DNX Corporation. Steven Holtzman is a board member or trustee of the Biotechnology Industry Organization (BIO), PMV Pharma (a private biotechnology company), the Berklee College of Music, and the Board of Overseers of the Isabella Stewart Gardner Museum. He used to serve as a presidential appointee to the US National Bioethics Advisory Commission. Steven Holtzman received his B.A. from Michigan State University and B.Phil. graduate degree from Oxford University which he attended as a Rhodes Scholar. "I am delighted to join Molecular Partners, one of the most exciting biotech stories in Europe," added Steven Holtzman. "DARPins represent a new powerful class of small protein therapies, and the stage is set to continue to build on the success laid out in a strong clinical and preclinical pipeline and several impressive alliances. I look forward to supporting Molecular Partners in these exciting times and to being part of its continued success." Notes to editors: About Molecular Partners AG Molecular Partners is a clinical-stage biotech company that is developing a new powerful class of therapies known as DARPins. DARPins are potent, specific and versatile small protein therapies that are designed to function as a team to select and stop multiple disease-specific targets to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the management of serious diseases, including cancer and sight-threatening disorders. Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The most advanced product candidate is abicipar pegol, for which the company's partner Allergan plans to initiate a Phase III clinical trial in wet AMD. The company has ongoing research and development partnerships with leading pharmaceutical companies including Allergan, Roche and Janssen and is backed by established biotech investors. For more information regarding Molecular Partners, please visit: www.molecularpartners.com. For further details please contact: Rolf Schläpfer Hirzel.Neef.Schmid.Konsulenten Tel: +41 (0)43 344 4242 [email protected] Dr. Christian Zahnd, CEO [email protected] Dr. Patrick Amstutz, COO [email protected] Tel: +41 (0) 44 755 77 00 Press release (PDF) ProviderChannelContactTensid Ltd., Switzerland www.tensid.chnewsbox.ch www.newsbox.chProvider/Channel related enquiries [email protected] +41 41 763 00 50 (c) 2014 Tensid Ltd., Switzerland. |